Google
MBRX — MOLECULIN BIOTECH INC (Healthcare >> Biotechnology)
MBRX FAQ
What is MBRX's P/E ratio?
MOLECULIN BIOTECH INC (MBRX) currently trades at a P/E ratio of 0.86.
What is MBRX's ROE?
MOLECULIN BIOTECH INC reports a Return on Equity (ROE) of -199.78%.
What is MBRX's dividend yield?
MOLECULIN BIOTECH INC offers a dividend yield of 0.00%.
What is MBRX's Deepscope Quality Score?
Deepscope rates MBRX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MBRX?
Deepscope's AI Timing Score for MBRX is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MBRX belong to?
MOLECULIN BIOTECH INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.51
Price
0.05
(2.03%)
Day Change
|
|
|---|
MBRX, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.51 |
| PBV / Sector |
0.88 / 4.58
GREAT
|
| Earning Per Share | -5.72 |
| PE / Sector |
0.86 / 17.10
GREAT
|
| PEG or PE/Growth / Sector |
-0.02 / 0.52
|
| Average 1M Daily Value |
0.74 M
GREAT
|
| Average 1W Daily Value |
0.85 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:04 |
| Symbol | MBRX |
| Name | MOLECULIN BIOTECH INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 5.34 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 13.31 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5300 Memorial Drive, Houston, TX, United States, 77007
Phone: 713 300 5160
Website: https://moleculin.com
Sector: Healthcare >> Biotechnology
Description: Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
